| dc.creator | Santini-Oliveira, Marilia | |
| dc.creator | Grinsztejn, Beatriz | |
| dc.date | 2018-10-04T18:57:38Z | |
| dc.date | 2018-10-04T18:57:38Z | |
| dc.date | 2014 | |
| dc.date.accessioned | 2023-09-26T20:35:47Z | |
| dc.date.available | 2023-09-26T20:35:47Z | |
| dc.identifier | SANTINI-OLIVEIRA, M.; GRINSTEJN, B. Adverse drug reactions associated with antiretroviral therapy during pregnancy. Expert Opinion on Drug Safety, v. 13, n. 12, p. 1623-1652, 2014. | |
| dc.identifier | 1474-0338 | |
| dc.identifier | https://www.arca.fiocruz.br/handle/icict/29363 | |
| dc.identifier | 10.1517/14740338.2014.975204 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/8860269 | |
| dc.description | Antiretroviral (ARV) drug use during pregnancy significantly reduces mother-to-child HIV transmission, delays disease progression in the women and reduces the risk of HIV transmission to HIV-serodiscordant partners. Pregnant women are susceptible to the same adverse reactions to ARVs as nonpregnant adults as well as to specific pregnancy-related reactions. In addition, we should consider adverse pregnancy outcomes and adverse reactions in children exposed to ARVs during intrauterine life. However, studies designed to assess the safety of ARV in pregnant women are rare, usually with few participants and short follow-up periods. | |
| dc.description | 2028-08-30 | |
| dc.format | application/pdf | |
| dc.language | eng | |
| dc.rights | restricted access | |
| dc.subject | HIV | |
| dc.subject | Adverse drug reactions | |
| dc.subject | Antiretroviral | |
| dc.subject | Pregnancy | |
| dc.title | Adverse drug reactions associated with antiretroviral therapy during pregnancy | |
| dc.type | Article | |
